Clinical Trials Browser

Phase 1/2 × Recurrence × aumolertinib × Clear all

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Recurrence